Early versus late extubation after surfactant replacement therapy for respiratory distress syndrome  by Garib, Mohamed et al.
Egyptian Pediatric Association Gazette (2015) 63, 1–5HO ST E D  BY Contents lists available at ScienceDirect
Egyptian Pediatric Association Gazette
journal homepage: http://www.elsevier.com/locate/epagEarly versus late extubation after surfactant
replacement therapy for respiratory distress
syndrome* Corresponding author.
E-mail address: drsderaz@hotmail.com (S. Deraz).
Peer review under responsibility of Egyptian Pediatric Association
Gazette.
http://dx.doi.org/10.1016/j.epag.2015.02.003
1110-6638 ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric Association.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Mohamed Garib a, Niveen Salama b, Salem Deraz a,*a Department of Pediatrics, Menouﬁa University, Egypt
b Department of Pediatrics, Cairo University, EgyptReceived 6 January 2015; revised 6 February 2015; accepted 8 February 2015
Available online 28 February 2015KEYWORDS
Surfactant;
Extubation;
Respiratory distressAbstract Patients and methods: Ninety patients treated by surfactant replacement therapy were
included in the study. Patients were divided into 2 groups; group A consists of patients who were
extubated early within 24 h after surfactant administration and group B consists of patients who
were extubated after 24 h from surfactant administration.
Results: 59 patients were extubated early (within 24 h after surfactant administration) while 31
patients were extubated late (after 24 h from surfactant administration). Patients in group B (late
extubation group) had a longer duration of CPAP (41.53 + 9.74 h in group B versus
17.30 + 4.03 h in group A), a longer duration of total oxygen administration (73.41 + 11.24 h in
group B versus 45.33 + 5.22 h in group A) and a longer duration of hospital stay
(171.88 + 75.74 h in group B versus 106.82 + 52.79 h in group A) than patients in group A (early
extubation group). 41 (69.50%) Patients who were extubated early received surfactants at or before
the age of 6 h while 22 (70.97%) patients who were extubated late received surfactants after the age
of 6 h. Regarding complications, 6 patients had transient bradycardia (6.7%), 4 patients had pneu-
mothorax (4.4%) and 4 patients had pulmonary hemorrhage (4.4%).
Conclusion: Early administration of surfactants is associated with early extubation. Patients who
were extubated early (most of them had an early administration of surfactants) had a lower chance
for re-intubation, less duration of total oxygen administration and less hospital stay.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Artiﬁcial respiratory support and surfactant replacement are
cornerstones of the management of infant respiratory distress
syndrome (RDS). Respiratory support strategies include nasal
continuous positive airway pressure (NCPAP) and mechanical
ventilation (MV), which are effective in reducing mortality and
Nomenclature
CPAP continuous positive airway pressure
CS cesarean section
FIO2 fraction of inspired oxygen
INSURE intubation-surfactant-extubation
MV mechanical ventilation
NCPAP nasal continuous positive airway pressure
NICU neonatal intensive care unit
NVD normal vaginal delivery
RDS respiratory distress syndrome
2 M. Garib et al.morbidity due to RDS.1,2 Early discontinuation of mechanical
ventilation presents difﬁculties, and up to 25–52% of preterm
neonates experience extubation failure (EF).3–5
A method of respiratory assistance, commonly referred to
as INSURE (intubation-surfactant-extubation), reduced the
need for MV, the duration of respiratory support and oxygen
supplementation, further surfactant administrations, and the
length of stay in the neonatal intensive care unit (NICU).6
Although beneﬁcial in clinical practice, the INSURE method
cannot be universally applied to all preterm neonates with
RDS and is unsuccessful in a particular section of this popula-
tion.6 The INSURE failure rate reported in the literature
ranges from 9% to 50% according to the different populations
included and the different criteria used for the deﬁnition of
failure.7–9
The purpose of this study was to compare outcomes
between two strategies of surfactant administration in infants
with RDS; early surfactant administration (within 6 h after
birth) followed by prompt extubation, compared with later
use of surfactants followed by continued mechanical
ventilation.Patients and methods
The study was done in a tertiary care hospital in the Arab Gulf
area after approval of the institutional review board (IRB) as a
prospective – cohort – study. All newborn infants (full or pre-
term) who were admitted to the NICU with respiratory dis-
tress syndrome, born between January 2012 and December
2013 and treated by surfactant replacement therapy were
included in the study. 90 patients fulﬁlled our criteria. Their
data were collected including, sex, gestational age, mode of
delivery, maternal chronic illness, antenatal steroids for moth-
ers, Apgar scoring at 1 and 5 min, age of surfactant adminis-
tration, mode of ventilation, failure of extubation, maximum
FIO2, duration of oxygen supply and duration of hospital stay.
Patients were divided retrospectively into two groups. The ﬁrst
group consists of patients who were extubated early within
24 h after surfactant administration and the second group con-
sists of patients who were extubated after 24 h from surfactant
administration.
Exclusion criteria included all infants with major congenital
anomalies (infants delivered with known syndrome or with
chromosomal abnormalities) or patients with incomplete med-
ical records. Our policy was to give any infant who was diag-
nosed to have RDS early surfactant within 6 h after delivery;
however some infants received late surfactant administration
because they were born outside our center and referred to us
later for further management.
Early surfactant administration was provided to symp-
tomatic infants within the ﬁrst few hours after birth, shortlyafter the onset of respiratory symptoms, often before the need
for endotracheal intubation to treat respiratory failure. Later
surfactant therapy was deﬁned as surfactant administration
at or near the time of respiratory failure when the newborn
requires intubation and mechanical ventilation to maintain
oxygenation.
Statistical analysis
Data were entered into the SPSS software program (SPSS 19
Inc., Chicago, IL, USA). Incidence rate and 95% conﬁdence
interval will be reported. For signiﬁcant comparison relative
risk and logistic regression will be used to compare late pre-
term and full term infants. For ordinal variables, the Wilcox
on rank sum test will be used for comparison of medians.
Results
The study was done over 2 years, 90 infants’ met the deﬁned
criteria from January 2012 till December 2013. 59 patients
were extubated early (within 24 h after surfactant administra-
tion) while 31 patients were extubated late (after 24 h from sur-
factant administration). 63 patients (70%) were males while 27
patients (30%) were females. 38 patients (42.2%) were born by
normal vaginal delivery while 52 patients (57.8%) were born
by cesarean section. The mothers of 39 patients (43.33%)
had chronic illness. Only 15 mothers (16.67%) received antena-
tal steroids to enhance fetal lung maturity. 86 patients
(95.55%) received one dose of surfactant only one time, while
4 patients (4.45%) received two doses. 13 patients were re-in-
tubated (6%), two of them from group A and eleven from
group B with signiﬁcant statistical difference between the 2
groups. 86 patients were put on CPAP (95.55%), while only
4 patients (4.45%) were extubated to room oxygen in the incu-
bator. After 72 h from extubation 19 patients were on SIMV
(21.11%), 24 patients on CPAP (26.67%), 12 patients were
on incubator oxygen (13.33%) and 35 patients on room air
(38.89%). After 120 h from extubation 2 patients were on
SIMV (2.22%), 8 patients on CPAP (8.89%), 12 patients on
incubator oxygen (13.33%) and 68 patients on room air
(75.56%). Regarding the complications, 6 patients had tran-
sient bradycardia (6.7%), 4 patients had pneumothorax
(4.4%) and 4 patients had pulmonary hemorrhage (4.4%).
All patients in group A were successfully discharged home
and 2 patients from group B expired later due to sepsis
(2.2%), (Table 1).
Patients in group B (late extubation group) had a longer
duration of CPAP (41.53 + 9.74 h in group B versus
17.30 + 4.03 h in group A), a longer duration of total oxygen
administration (73.41 + 11.24 h in group B versus
45.33 + 5.22 h in group A) and a longer duration of hospital
Table 1 Characteristics of study groups.
Variable Early extubation (A) Late extubation (B) Total P
Number = 59 Number = 31
Sex
Males 40 23 63 (70.00) 0.53
Females 19 8 27 (30.00)
Mode of labor
NVD 23 15 38 (42.20) 0.76
CS 36 16 52 (57.80)
Maternal chronic diseases
Yes 25 14 39 (43.33) 0.77
No 34 17 51 (56.67)
Maternal steroids
Yes 8 7 15 (16.67) 0.55
No 51 24 75 (83.33)
Number of doses
Once 57 29 86 (95.55) 1.00
Twice 2 2 4 (4.45)
Re-intubation
Yes 2 11 13 (6.00) <0.001
No 57 20 77 (94.00)
Mode of ventilation after extubation
CPAP 55 31 86 (95.55) 0.54
O2 Incubator 4 0 4 (4.45)
Respiratory support at 72 h from surfactant
Room air 30 5 35 (38.89) <0.01
CPAP 18 6 24 (26.67) <0.05
SIMV 4 15 19 (21.11) <0.05
O2 incubator 7 5 12 (13.33) 0.36
Respiratory support at 120 h from surfactant
SIMV 0 2 2 (2.22) <0.05
Room air 50 18 68 (75.56) <0.01
CPAP 4 4 8 (8.89) 0.52
O2 incubator 5 7 12(13.33) 0.14
Complications
Transient bradycardia 3 3 6 (6.7) 0.52
Pneumothorax 1 3 4 (4.4) 0.13
Pulmonary hemorrhage 1 3 4 (4.4) 0.13
Mortality 0 2 2 (2.22) <0.05
Table 2 Comparison between early and late extubation in relevance to study quantitative parameters.
Variable Early extubation (n= 59) Late extubation (n= 31) P value
Group A Group B
Mean + SD Mean + SD
Gestational age in weeks 34.39 + 2.35 33.71 + 2.68 0.356
Apgar score 1 m 5.8485 + 1.93 5.1176 + 1.49 0.181
Apgar score 5 m 9.2424 + 0.79 9.0588 + 1.34 0.546
Birth weight 2.2812 + 0.63 2.0982 + 0.71 0.360
Length 45.9848 + 4.08 44.5882 + 4.84 0.288
HC 31.7121 + 2.70 31.5588 + 2.69 0.850
Age of surfactant in hours 5.72 + 2.76 6.81 + 3.87 0.744
Duration of CPAP after extubation in hours 17.30 + 4.03 41.53 + 9.74 <0.001
Duration of total oxygen administration in hours 45.33 + 5.22 73.41 + 11.24 <0.01
Maximum FIO2 % 41.91 + 10.63 43.53 + 10.86 0.615
Duration of hospitalization in hours 106.82 + 52.79 171.88 + 75.74 <0.001
Surfactant replacement therapy for respiratory distress syndrome 3stay (171.88 + 75.74 h in group B versus 106.82 + 52.79 h in
group A) than patients in group A (early extubation group),
(Table 2).Gestational age did not affect the timing of extubation. 41
(69.50%) patients who were extubated early received surfac-
tants at or before the age of 6 h while 22 (70.97%) patients
Table 3 Relation between the gestational age, age at surfactant administration (h) and extubation.
Variable Early extubation Late extubation Total P value
Number (%) Number (%)
Gestational age <30 weeks 5 4 9 (10.00) <0.01
>30–37 weeks 52 26 78 (86.700)
>37 weeks 2 1 3 (3.3.00)
Age at surfactant
administration in hours
Early admin (<6 h) 41 (69.50%) 9 (29.03%) 50 (55.56) <0.01
Late admin (>6 h) 18 (30.50%) 22 (70.97%) 40 (44.44)
Total 59 (100%) 31 (100%)
P value <0.001 <0.001
4 M. Garib et al.who were extubated late received surfactants after the age of
6 h, (Table 3).
Discussion
Respiratory distress syndrome (RDS) is the single most impor-
tant cause of illness and death in preterm infants. Common
treatments for RDS include supplemental oxygen and nasal
continuous positive airway pressure (NCPAP). For severe
RDS, surfactant administration during mechanical ventilation
is used. Although treating RDS with surfactants improves clin-
ical outcomes, mechanical ventilation can cause lung injury in
preterm infants with RDS and contribute to the development
of chronic lung disease (oxygen requirements at 36 weeks)
and bronchopulmonary dysplasia (requirement for supplemen-
tary oxygen at 28 days, BPD).10
An important question is whether giving early surfactants
with planned brief mechanical ventilation followed by prompt
extubation (to NCPAP) is better than selectively giving surfac-
tants when RDS has worsened causing respiratory insufﬁcien-
cy necessitating mechanical ventilation.
The purpose of this study was to compare outcomes
between the two strategies of surfactant administration in
infants with RDS; early surfactant administration (within 6 h
after birth) followed by prompt extubation, compared with
later use of surfactants followed by continued mechanical
ventilation.
The respiratory distress syndrome (RDS) can be treated
according to the INtubation-SURfactant-Extubation
(INSURE) procedure [10]. However, INSURE failure, with
the need for re-intubation and mechanical ventilation (MV),
is common.11–16 Keeping neonates at high risk of INSURE
failure intubated on MV after surfactant administration may
prevent a re-intubation procedure, which may decrease the
morbidity and mortality of neonates because re-intubation is
associated with airway injuries,17 blood pressure deviations,
and post-extubation atelectasis.18
In the current study surfactants were administrated early to
50 patients (55.56%) and were given late to 40 patients
(44.44%), 69.5% of patients who received surfactants early
were extubated early while only 30.50% who had late surfac-
tant administration were extubated early (p value was
<0.001), (Table 3).
Early surfactant administration is provided to symptomatic
infants within the ﬁrst few hours after birth, shortly after the
onset of respiratory symptoms, often before the need for
endotracheal intubation to treat respiratory failure. Latersurfactant therapy is deﬁned as surfactant administration at or
near the time of respiratory failure when the newborn requires
intubation andmechanical ventilation tomaintain oxygenation.
Early selective surfactant therapy compared with later therapy
offers the advantage of restoring surfactant pools before lung
inﬂammation and protein-containing ﬂuid inﬂux inactivates
the native surfactants causing worsening gas exchange.19
Stevens and Sinkin reported in their study that surfactant
replacement therapy (SRT) early in the course of RDS, before
surfactant inactivation plays a prominent role in lung patho-
physiology, is superior to later SRT when lung disease is more
advanced.19
In a systematic review of studies comparing early vs late
surfactant administration, early SRT decreased neonatal mor-
tality (RR, 0.87; 95% CI, 0.77–0.99), pneumothorax (RR,
0.70; 95% CI, 0.59–0.82), and pulmonary interstitial emphyse-
ma (RR, 0.63; 95% CI, 0.43–0.93). In addition, the incidence
of chronic lung disease or death at 36 weeks postmenstrual
age was reduced (RR, 0.84; 95% CI, 0.75–0.93).20
In this study it was proven that patients who were extubat-
ed early (most of them had early administration of surfactants)
had a lower chance for re-intubation, (Table 1), less duration
of CPAP, less duration of oxygen administration and less hos-
pital stay, (Table 2).
Early nCPAP, mechanical ventilation and surfactant treat-
ment are all established interventions for preterm infants with
RDS. The methods complement each other, but the question
of an optimal strategy remains unanswered. The success of
CPAP care is very dependent on experience and therefore ade-
quate training of both medical and nursing staff is essential. To
date neither early nCPAP nor mechanical ventilation can be
said to be superior. The ability to give surfactants during
nCPAP appears to be important in every preterm infant and
more mature infants with severe RDS.21
Since the duration of mechanical ventilation via the endo-
tracheal tube has a direct correlation with BPD, noninvasive
ventilation (NIV) after a brief period of IVET using nasal con-
tinuous positive airway pressure (nCPAP) and nasal intermit-
tent positive pressure ventilation (NIPPV) are being evaluated
as ways of protecting the lungs of preterm infants. NIV
appears to be beneﬁcial in the management of apnea of prema-
turity, for prevention of extubation failure, as well as in the ini-
tial management of RDS. nCPAP can be delivered using
conventional mechanical ventilators, bubble CPAP or infant
ﬂow driver systems.22–25
In the Cochrane Database Systematic Review study (2007),
the authors reported that early surfactant replacement therapy
Surfactant replacement therapy for respiratory distress syndrome 5reduces mortality and pulmonary complications in ventilated
infants with respiratory distress syndrome (RDS) compared
with later selective surfactant administration. However, con-
tinued post-surfactant intubation and ventilation are risk fac-
tors for bronchopulmonary dysplasia (BPD).10
Conclusion
Early administration of surfactants is associated with early
extubation. Patients who were extubated early (most of them
had early administration of surfactants) had a lower chance
for re-intubation, less duration of CPAP, less duration of total
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